{"pmid":32425261,"pmcid":"PMC7227496","title":"Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.","text":["Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism.","*COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.*Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.*Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.","Thromb Res","Galeano-Valle, F","Oblitas, C M","Ferreiro-Mazon, M M","Alonso-Munoz, J","Del Toro-Cervera, J","Demelo-Rodriguez, P","32425261"],"abstract":["*COVID-19 pneumonia could be associated with an increased risk of venous thrombosis.*Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients.*Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low."],"journal":"Thromb Res","authors":["Galeano-Valle, F","Oblitas, C M","Ferreiro-Mazon, M M","Alonso-Munoz, J","Del Toro-Cervera, J","Demelo-Rodriguez, P"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425261","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.thromres.2020.05.017","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667352728760745984,"score":9.490897,"similar":[{"pmid":32379918,"title":"Coagulopathy of COVID-19 and antiphospholipid antibodies.","text":["Coagulopathy of COVID-19 and antiphospholipid antibodies.","Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported.","J Thromb Haemost","Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M","32379918"],"abstract":["Recently in the Journal of Thrombosis and Haemostasis, Harzallah and colleagues report the results of antiphospholipid antibody testing in a series of 56 patients with confirmed or suspected SARS-CoV-2 infection.[1] Twenty-five patients were found to be positive for lupus anticoagulants, while five patients had either anticardiolipin or anti-beta2-glycoprotein I antibodies. The isotypes for the anticardiolipin and anti-beta2-glycoprotein I antibodies were reportedly IgG and IgM, although specific antibody titers and details of which were found in combination with a lupus anticoagulant in three overlap patients were not reported."],"journal":"J Thromb Haemost","authors":["Connell, Nathan T","Battinelli, Elisabeth M","Connors, Jean M"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379918","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14893","topics":["Diagnosis"],"weight":1,"_version_":1666262687574654978,"score":216.462},{"pmid":32379935,"title":"Response to \"Lupus anticoagulant is frequent in patients with Covid-19\".","text":["Response to \"Lupus anticoagulant is frequent in patients with Covid-19\".","We appreciate the opportunity to respond to the letter from Dr. Ines Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-beta2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain.","J Thromb Haemost","Tang, Ning","32379935"],"abstract":["We appreciate the opportunity to respond to the letter from Dr. Ines Harzallah, et al. Antiphospholipid antibody assays including lupus anticoagulant (LAC), anticardiolipin and anti-beta2-glycoprotein I have also been performed in dozens of our patients, however, very few of them got positive results, we don't think that antiphospholipid antibody exists universally in COVID-19 patients. In addition, two of the three reported cases with antiphospholipid antibodies mentioned in the letter [1] also seem to meet the International Society on Haemostasis and Thrombosis (ISTH) criteria of disseminated intravascular coagulation [2], the causality between antiphospholipid antibodies and thrombosis in these cases is still uncertain."],"journal":"J Thromb Haemost","authors":["Tang, Ning"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379935","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jth.14890","weight":0,"_version_":1666262687570460673,"score":192.9611},{"pmid":32324958,"title":"Lupus anticoagulant is frequent in patients with Covid-19.","text":["Lupus anticoagulant is frequent in patients with Covid-19.","Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients.","J Thromb Haemost","Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard","32324958"],"abstract":["Patients hospitalized for Covid-19 severe infection are more prone to excessive coagulation activation leading to thrombotic events. Tang et al.1 discussed the importance of high D-dimer and Fibrin degradation product level to determine the patient prognostic and the risk of thrombosis. However they did not look at lupus anticoagulant (LAC). Zhang et al. described, three cases of thrombosis associated with antiphospholipid antibodies represented by anticardiolipin (aCL) and anti-beta2-glycoprotein I (abeta2GPI)2. No lupus anticoagulant was detected in any of the patients."],"journal":"J Thromb Haemost","authors":["Harzallah, Ines","Debliquis, Agathe","Drenou, Bernard"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324958","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jth.14867","topics":["Treatment"],"weight":1,"_version_":1666138493881942016,"score":166.05853},{"pmid":32419710,"pmcid":"PMC7224655","title":"Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.","text":["Deep venous thrombosis in a non-critically ill patient with novel COVID-19 infection.","*COVID-19 infection is associated with hypercoagulability and a prothrombotic state.*Little is understood about the prevalence of venous thromboembolism in mild disease.*We present a case of mild COVID-19 complicated by extensive deep venous thrombosis.","Thromb Res","Nauka, Peter C","Oran, Erick","Chekuri, Sweta","32419710"],"abstract":["*COVID-19 infection is associated with hypercoagulability and a prothrombotic state.*Little is understood about the prevalence of venous thromboembolism in mild disease.*We present a case of mild COVID-19 complicated by extensive deep venous thrombosis."],"journal":"Thromb Res","authors":["Nauka, Peter C","Oran, Erick","Chekuri, Sweta"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419710","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.thromres.2020.05.015","topics":["Case Report"],"weight":1,"_version_":1667159284436172802,"score":130.0196},{"pmid":32451823,"title":"Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.","text":["Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.","Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 microg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level >/= 1.0 microg/ml and >/= 3 microg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 mug/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.","J Thromb Thrombolysis","Artifoni, Mathieu","Danic, Gwenvael","Gautier, Giovanni","Gicquel, Pascal","Boutoille, David","Raffi, Francois","Neel, Antoine","Lecomte, Raphael","32451823"],"abstract":["Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 microg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level >/= 1.0 microg/ml and >/= 3 microg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 mug/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies."],"journal":"J Thromb Thrombolysis","authors":["Artifoni, Mathieu","Danic, Gwenvael","Gautier, Giovanni","Gicquel, Pascal","Boutoille, David","Raffi, Francois","Neel, Antoine","Lecomte, Raphael"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451823","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s11239-020-02146-z","keywords":["covid-19","d-dimer","pulmonary embolism","venous thromboembolism"],"locations":["French","thromboprophylaxis","thromboprophylaxis","heparin","thromboprophylaxis"],"countries":["France"],"countries_codes":["FRA|France"],"e_drugs":["Heparin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667881798549372928,"score":129.82693}]}